Talley Group Ltd review of 2007
Posted: Friday, February 29th, 2008
Talley are pleased to report that 2007 has been another successful year for the company, as well as achieving a record turnover for the 12 months ended 31st October 2007.
Significant capital investment for tooling and equipment at the Romsey site has brought about improved efficiency and cost saving. This has enabled the company to competitively price the goods and services it provides.
Good control of overheads and a focus on customer needs has meant that Talley have been able to buck the industry trend by posting much improved turnover and profitability figures for 2007 compared to 2006.
The directors are actively seeking further acquisition opportunities and believe that the company is well set to continue with its growth pattern in 2008.
The success of the pressure area care products including the Quattro™ and Base™ range of pressure relieving mattresses and seating systems has directly resulted in Talley being awarded 2 of the largest mattress tenders issued by the NHS in recent years. Furthermore international business, in both the USA and Rest of World continues to flourish, with expectations for further growth.
Negative Pressure Wound Therapy products from the Venturi™ range has seen a dramatic growth both in the UK and internationally since launch in July 2007. The continued acceptance as demonstrated in clinical case studies along with the award onto a number of significant contracts with many customers purchasing and renting the systems clearly demonstrates Talley’s ability to develop and manufacture state of the art medical devices.
Talley Group Ltd have also successfully integrated the Sylvan range of specialist duvets and pillows into the company portfolio, and have also seen a growth in this area with Trust’s identifying that the products help reduce laundry bills and linen replacement costs, whilst also reducing nurses bed making time and enhancing patient care and comfort.
TECare™ antimicrobial fluid continues to protect patients from the risk of Healthcare Acquired Infections including Clostridium difficile and MRSA. This highly effective and ultra safe antimicrobial product, which is harmless to man, but kills a broad spectrum of bacteria and – uniquely – prevents further colonisation for up to four weeks, has shown continued strong growth and exciting new test data will be published soon.
Group Operations Manager Kevin Mearns said:
Following on from last years success we have continued our growth, clearly demonstrating that our product range and strategy of investment in UK manufacturing, with research and development focusing on quality, value, and innovation has driven our expansion in our UK and International markets. This expansion has meant we have also grown our customer support functions with the addition of more clinical and technical staff dedicated to delivering a first class service.
With the directors continuing to develop the company further through acquisition and developments into new product areas we look forward to continuing to respond to our customers needs quickly and efficiently, whilst keeping prices competitive for the NHS and private facilities alike.